Globus Medical

Globus Medical is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company provides a portfolio of technologies that are used to treat musculoskeletal conditions of the spine, extremities and pelvis. The company's product categories are: Musculoskeletal Solutions, consisting of implantable devices, biologics, accessories, and surgical instruments used in spinal, orthopedic and neurosurgical procedures; and Enabling Technologies, consisting of computer-assisted intelligent systems designed to improve a surgeon's capabilities and streamline surgical procedures to improve patient care and reduce radiation exposure for all involved.
  • TickerGMED
  • ISINUS3795772082
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

Globus Medical Inc: 1 director sold after exercising options/sold

A director at Globus Medical Inc sold after exercising options/sold 217,075 shares at 64.200USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Globus Medical Inc: 1 director sold after exercising options/sold

A director at Globus Medical Inc sold after exercising options/sold 217,075 shares at 64.200USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under...

MarketLine Department

Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report

Summary Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Zimmer Biomet Holdings Inc. (Zimmer Biomet or 'the company') is a designer, manufacturer and marketer of medical devices. The company offers sports medicine, orthopaedic reconstructive products, extremities, spine, biologics and trauma products, craniomaxillofacial and thoracic p...

MarketLine Department

Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report

Summary Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Integra LifeSciences Holdings Corporation (Integra or 'the company') is a provider of medical technology solution. The company offers regenerative technologies, surgical solutions, and orthopedics and tissue technologies. Its products find application in burn and ti...

MarketLine Department

Marinus Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Marinus Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Marinus Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its co...

Valens Research

Valens Equity Insights and Inflections - 2020 10 13

WMT currently trades above averages relative to Uniform earnings, with a 29.7x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to grow from 9% in 2020 to 15% through 2025, accompanied by 1% Uniform asset shrinkage going forward. Meanwhile, analysts have less bullish expectations, projecting Uniform ROA to maintain 9% levels through 2022, accompanied by 2% Uniform asset shrinkage. Furthermore, management appears concerned about eCommerce, inventory, and Flipkart. Current valuations appear to be pricing in overly bullish expectations for WMT, and if the compan...

Valens Research

GMED - Embedded Expectations Analysis - 2020 10 09

Globus Medical, Inc. (GMED:USA) currently trades above historical averages relative to UAFRS-based (Uniform) earnings, with a 29.2x Uniform P/E. Even at these levels, the market has bearish expectations for the firm, and management may be concerned about revenue declines, the potential of product launches, and losing market share Specifically, management may lack confidence in their ability to mitigate revenue and gross profit declines and their decision to maintain their historical pricing strategy. Moreover, they may be concerned about the potential of their spine product development team's...

For GLOBUS MEDICAL INCO., the environment deterioration entails a downgrade to Neutral

GLOBUS MEDICAL INCO. (US), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener just confirmed the fundamental rating of 2 stars out of 4, as well as the stock market behaviour of the title as moderately risky. However, environmental deterioration penalises the general evaluation, which is downgraded to Neutral. As of the analysis date August 4, 2020, the closing price was USD 48.79 and its expected value was estimated at USD 48.48.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch